AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25795145 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-Up to Quit (SUTQ) intervention that integrates advice for low-to-moderate intensity physical activity (LMPA) with standard smoking cessation counseling (SCC)
Number of subjects: 0
Study 25795145 — intervention group
Group type: COMPARATOR
Intervention: Standard smoking cessation counseling (SCC) control
Number of subjects: 0
Study 25795145 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-Up to Quit (SUTQ) intervention
Number of subjects: 0
Study 23945243 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 46
Study 23945243 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed
Number of subjects: 46
Study 20154213 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD standard risk (MRD-SR) patients, n = 1348
Number of subjects: 3184
Study 20154213 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD intermediate risk (MRD-IR) patients, n = 1647
Number of subjects: 3184
Study 20154213 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD high risk (MRD-HR) patients, n = 189
Number of subjects: 3184
Study 18277935 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding infants at the 4-6 week visit (with negative HIV-1 results at that visit)
Number of subjects: 2052
Study 18277935 — intervention group
Group type: EXPERIMENTAL
Intervention: More advanced maternal HIV-1 disease (lower CD4 counts, higher plasma viral loads)
Number of subjects: 2052
Study 15721027 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (0.625 mg/day of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate)
Number of subjects: 61
Study 15721027 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins (400 IU of Vitamin E and 500 mg of Vitamin C twice daily)
Number of subjects: 61
Study 15721027 — intervention group
Group type: COMPARATOR
Intervention: Placebo for hormone therapy
Number of subjects: 61
Study 15721027 — intervention group
Group type: COMPARATOR
Intervention: Placebo for antioxidant vitamins
Number of subjects: 61
Study 12893194 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (500 mg/m(2)/day days 1‐5) with Topotecan (1.25 mg/m(2)/day days 1‐5)
Number of subjects: 30
Study 12893194 — intervention group
Group type: COMPARATOR
Intervention: Topotecan (1.5 mg/m(2)/day days 1‐5)
Number of subjects: 30
Study 10534084 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat tip cervical cryotherapy
Number of subjects: 117
Study 10534084 — intervention group
Group type: EXPERIMENTAL
Intervention: Shallow conical tip cervical cryotherapy
Number of subjects: 117
Study 8640909 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower oil-based diet (SO)
Number of subjects: 59
Study 8640909 — intervention group
Group type: COMPARATOR
Intervention: Low erucic acid rapeseed oil-based diet (RO)
Number of subjects: 59
Study 1752117 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin (0.1 to 10 nmol in 10 microliters)
Number of subjects: 0
Study 1752117 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin (5- or 30-minute intervals)
Number of subjects: 0
Study 1752117 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin (various doses)
Number of subjects: 0
Study 6279061 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical administration of delta 9-tetrahydrocannabinol (THC)
Number of subjects: 0
Study 6279061 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone
Number of subjects: 0
Study 30501481 — intervention group
Group type: COMPARATOR
Intervention: Bendamustine plus rituximab
Number of subjects: 547
Study 30501481 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 547
Study 30501481 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib plus rituximab
Number of subjects: 547
Study 30501481 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 547
Study 27080315 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-arm blood pressure difference (IAD) ≥5 mmHg
Number of subjects: 3350
Study 27080315 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-arm blood pressure difference (IAD) ≥10 mmHg
Number of subjects: 3350
Study 27080315 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-arm blood pressure difference (IAD) ≥15 mmHg
Number of subjects: 3350
Study 25023784 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (30 mg/day of elemental iron for 12 weeks)
Number of subjects: 200
Study 25023784 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron bis-glycinate chelate (30 mg/day of elemental iron for 12 weeks)
Number of subjects: 200
Study 22180580 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine replacement therapy (15 mg for 8 weeks)
Number of subjects: 925
Study 20686324 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 186
Study 20686324 — intervention group
Group type: COMPARATOR
Intervention: Control (non-pioglitazone group)
Number of subjects: 186
Study 18665187 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-of-life diagnosis and therapy (QoL system) implemented for breast cancer patients.
Number of subjects: 0
Study 17132382 — intervention group
Group type: EXPERIMENTAL
Intervention: treatment protocol based on a formalised expert opinion
Number of subjects: 208
Study 17132382 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 208
Study 12965976 — intervention group
Group type: EXPERIMENTAL
Intervention: Health enhancement programs in elderly populations
Number of subjects: 0
Study 12965976 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 11095656 — intervention group
Group type: EXPERIMENTAL
Intervention: High dialysate sodium concentration (H-Na(D))
Number of subjects: 0
Study 11095656 — intervention group
Group type: COMPARATOR
Intervention: Low dialysate sodium concentration (L-Na(D))
Number of subjects: 0
Study 8897029 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (continuous incremental cycling protocol at 55%, 70%, and 85% VO2peak)
Number of subjects: 64
Study 8897029 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (initial 6 min)
Number of subjects: 64
Study 8897029 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (at 70% and 85% VO2peak)
Number of subjects: 64
Study 8897029 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (at 12 min and 18 min)
Number of subjects: 64
Study 8897029 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 64
Study 1841409 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b (Intron A)
Number of subjects: 18
Study 1841409 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 6346029 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 0
Study 6346029 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 0
Study 30461510 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention for medial humeral epicondyle fractures
Number of subjects: 0
Study 30461510 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical management
Number of subjects: 0
Study 29411722 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg gabapentin tablet (Group G, n = 50)
Number of subjects: 100
Study 29411722 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet (Group P, n = 50)
Number of subjects: 100
Study 26409714 — intervention group
Group type: EXPERIMENTAL
Intervention: KatGuide method
Number of subjects: 109
Study 26409714 — intervention group
Group type: COMPARATOR
Intervention: Conventional forceps method
Number of subjects: 109
Study 26409714 — intervention group
Group type: EXPERIMENTAL
Intervention: KatGuide method (experienced operators)
Number of subjects: 109
Study 26409714 — intervention group
Group type: COMPARATOR
Intervention: Conventional forceps method (experienced operators)
Number of subjects: 109
Study 25128249 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress induction
Number of subjects: 117
Study 25128249 — intervention group
Group type: EXPERIMENTAL
Intervention: Paranoia induction
Number of subjects: 117
Study 25128249 — intervention group
Group type: COMPARATOR
Intervention: No induction
Number of subjects: 117
Study 23262451 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled MgSO(4)
Number of subjects: 76
Study 23262451 — intervention group
Group type: EXPERIMENTAL
Intervention: β(2‐)agonist
Number of subjects: 76
Study 23262451 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled MgSO(4) + β(2‐)agonist
Number of subjects: 76
Study 23262451 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% (placebo)
Number of subjects: 76
Study 19926254 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 400mg
Number of subjects: 12
Study 19926254 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin (PGB) 75mg
Number of subjects: 12
Study 17621471 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple imputation (MI) under missing at random (MAR) assumption
Number of subjects: 0
Study 17621471 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted average of parameter estimates from MI under MAR
Number of subjects: 0
Study 17621471 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed alternative method for NMAR
Number of subjects: 0
Study 15924595 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 gastrectomy with splenectomy and distal pancreatectomy
Number of subjects: 33
Study 12683469 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 h sleep per night for 14 days
Number of subjects: 48
Study 12683469 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 h sleep per night for 14 days
Number of subjects: 48
Study 12683469 — intervention group
Group type: COMPARATOR
Intervention: 0 h sleep for 3 days (total sleep deprivation)
Number of subjects: 48
Study 12683469 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 h or less sleep per night
Number of subjects: 48
Study 12683469 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative wakefulness in excess of 15.84 h
Number of subjects: 48
Study 10234493 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% (n = 22)
Number of subjects: 68
Study 10234493 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 1% (n = 21)
Number of subjects: 68
Study 10234493 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (saline) (n = 20)
Number of subjects: 68
Study 8572664 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of deprenyl and/or 2,000 mg of tocopherol/day
Number of subjects: 800
Study 1711001 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon administration
Number of subjects: 16
Study 1711001 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 16
Study 1711001 — intervention group
Group type: COMPARATOR
Intervention: Control (patients who became RNA negative but exhibited RNA again)
Number of subjects: 16
Study 6261607 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% glucose (0.5 g/kg/h) and insulin (250 U/1,000 cc) with additional insulin up to 200 U/h, maximum 800 U/10 h; 500 ml 10% crystalline amino acid solution on the 1st postoperative day.
Number of subjects: 22
Study 6261607 — intervention group
Group type: COMPARATOR
Intervention: Ringer lactate as postoperative infusion (RL-group).
Number of subjects: 22
Study 31420398 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Treatment (HIT) - behaviour therapy, coaching and pharmacological advice
Number of subjects: 294
Study 31420398 — intervention group
Group type: COMPARATOR
Intervention: High-Intensity Treatment (HIT)
Number of subjects: 294
Study 28041600 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome Prioritisation Tool (OPT) consultation with GP
Number of subjects: 168
Study 28041600 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 168
Study 26912576 — intervention group
Group type: EXPERIMENTAL
Intervention: Sternal cables (Pioneer cabling system®)
Number of subjects: 273
Study 26912576 — intervention group
Group type: COMPARATOR
Intervention: Sternal wires (traditional sternal wiring in figure‐8 formation)
Number of subjects: 273
Study 25077420 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-μg rLP2086 dose
Number of subjects: 46
Study 25077420 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-μg rLP2086 dose
Number of subjects: 46
Study 25077420 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 46
Study 22361329 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 343466
Study 22361329 — intervention group
Group type: EXPERIMENTAL
Intervention: Model prediction
Number of subjects: 343466
Study 19027312 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of coronary collaterals
Number of subjects: 281
Study 17848425 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 301012 50-400 mg administered weekly via subcutaneous injection for 4 weeks
Number of subjects: 0
Study 17848425 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 301012
Number of subjects: 0
Study 15250199 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of shenmai and compound danshen injection (SM‐DS) before and after PCI
Number of subjects: 38
Study 15250199 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 38
Study 15250199 — intervention group
Group type: COMPARATOR
Intervention: Comparison between treated and control groups
Number of subjects: 38
Study 12583341 — intervention group
Group type: EXPERIMENTAL
Intervention: He Jie Decoction (HJD)
Number of subjects: 45
Study 12583341 — intervention group
Group type: COMPARATOR
Intervention: Usual western medicine (Control)
Number of subjects: 45
Study 9825335 — intervention group
Group type: EXPERIMENTAL
Intervention: ThinLine coradial bipolar leads
Number of subjects: 1068
Study 7847099 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (750 mg orally daily)
Number of subjects: 8
Study 7847099 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 8
Study 2483401 — intervention group
Group type: EXPERIMENTAL
Intervention: m‐BNCOD (mitoxantrone)
Number of subjects: 70
Study 2483401 — intervention group
Group type: COMPARATOR
Intervention: m‐BACOD (doxorubicin)
Number of subjects: 70
Study 1255259 — intervention group
Group type: EXPERIMENTAL
Intervention: Squibb Iodotope Diagnostic capsules
Number of subjects: 125
Study 1255259 — intervention group
Group type: COMPARATOR
Intervention: Squibb Iodotope Oral liquid
Number of subjects: 125
Study 1255259 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiocaps I‐131 (Abbott Laboratories)
Number of subjects: 125
Study 1255259 — intervention group
Group type: COMPARATOR
Intervention: Iodotope Oral liquid
Number of subjects: 125
Study 31434076 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib and Vorinostat (BV) therapy post-ASCT for 12 cycles (28-day cycles)
Number of subjects: 30
Study 31434076 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib and Vorinostat (BV) therapy post-ASCT
Number of subjects: 30
Study 31391201 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 0
Study 28515056 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement control exercise programme
Number of subjects: 3188
Study 28515056 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement control exercise programme (completed three or more weekly sessions)
Number of subjects: 3188
Study 28515056 — intervention group
Group type: COMPARATOR
Intervention: Standardised control exercise programme
Number of subjects: 3188
Study 28515056 — intervention group
Group type: COMPARATOR
Intervention: Overall match injury incidence
Number of subjects: 3188
Study 25400146 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg) infusion over 40 min
Number of subjects: 36
Study 23906260 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated screening for psychosocial and behavioural risks during pregnancy
Number of subjects: 1044
Study 23906260 — intervention group
Group type: COMPARATOR
Intervention: Initial screening for psychosocial and behavioural risks during pregnancy
Number of subjects: 1044
Study 21807250 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (5 μg daily)
Number of subjects: 388
Study 21807250 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 μg twice daily)
Number of subjects: 388
Study 21807250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388
Study 18930379 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment
Number of subjects: 0
Study 16452355 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (1 mg/kg every 8 hours for 5 days)
Number of subjects: 48
Study 16452355 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 48
Study 16452355 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 48
Study 15280144 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard FHR monitoring with ST segment analysis
Number of subjects: 51
Study 15280144 — intervention group
Group type: COMPARATOR
Intervention: Standard FHR monitoring without ST segment analysis
Number of subjects: 51
Study 11375843 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (initial dose 100 mg, can increase to 200 mg)
Number of subjects: 105
Study 11375843 — intervention group
Group type: COMPARATOR
Intervention: Morphine (initial dose 5 mg for body weight ≤ 70 kg or 10 mg for body weight > 70 kg, can increase to 15 or 20 mg)
Number of subjects: 105
Study 11375843 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 105
Study 11375843 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 105
Study 9231856 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable mesh (Polyglycolic acid, Dexon, Davis & Geck)
Number of subjects: 37
Study 9231856 — intervention group
Group type: COMPARATOR
Intervention: Non‐absorbable mesh (Polypropylene, Prolene, Ethicon Ltd)
Number of subjects: 37
Study 8115696 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 2 mg
Number of subjects: 38
Study 8115696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 3309251 — intervention group
Group type: EXPERIMENTAL
Intervention: Rodogyl for 2 weeks
Number of subjects: 56
Study 3309251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 31009097 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior repositioning splint (ARS)
Number of subjects: 69
Study 31009097 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior repositioning splint (ARS) with physical TMJ closed-lock reduction
Number of subjects: 69
Study 31009097 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy without ARS (Control)
Number of subjects: 69
Study 29089370 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (the major spicy component of chili pepper)
Number of subjects: 0
Study 29089370 — intervention group
Group type: EXPERIMENTAL
Intervention: Enjoyment of spicy foods
Number of subjects: 0
Study 29089370 — intervention group
Group type: COMPARATOR
Intervention: Control group (subjects who disliked spicy food)
Number of subjects: 0
Study 25262454 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 2289
Study 25262454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2289
Study 23679347 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 200 μg BID
Number of subjects: 291
Study 23679347 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 400 μg BID
Number of subjects: 291
Study 23679347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study 22050796 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.0 mg/kg at 3.3 mg/sec after normal saline pretreatment
Number of subjects: 120
Study 22050796 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.0 mg/kg at 3.3 mg/sec after lidocaine 0.5 mg/kg pretreatment
Number of subjects: 120
Study 22050796 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.0 mg/kg at 3.3 mg/sec after lidocaine 1.0 mg/kg pretreatment
Number of subjects: 120
Study 22050796 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.0 mg/kg at 50 mg/sec after normal saline pretreatment
Number of subjects: 120
Study 18516457 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% mannitol
Number of subjects: 60
Study 18516457 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phosphate
Number of subjects: 60
Study 18516457 — intervention group
Group type: COMPARATOR
Intervention: Sodium picosulphate
Number of subjects: 60
Study 18516457 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (10% mannitol, sodium phosphate, sodium picosulphate)
Number of subjects: 60
Study 18516457 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 16517330 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg) and succinylcholine (1 mg/kg)
Number of subjects: 120
Study 16517330 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg) and rocuronium (1 mg/kg)
Number of subjects: 120
Study 16517330 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (1 microg/kg) and succinylcholine (1 mg/kg)
Number of subjects: 120
Study 16517330 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (1 microg/kg) and rocuronium (1 mg/kg)
Number of subjects: 120
Study 15052769 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous estradiol gel combined with micronized progesterone (MP) or medroxyprogesterone acetate (MPA) for 25 days per month
Number of subjects: 60
Study 10779019 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimulation with a yellow-blue annular checkerboard reversing at frequencies of 1, 4, or 8 Hz
Number of subjects: 12
Study 9553982 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (active treatment)
Number of subjects: 817
Study 9553982 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 817
Study 9553982 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 817
Study 8463453 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 or 8 mg of sublingual buprenorphine for 21 days
Number of subjects: 20